Clinical trials: Progressive Ophthalmoplegia
Parkinson Disease, Progressive Supranuclear Palsy
Speech Accessibility Project
The goal of the Speech Accessibility Project at the University of Illinois Beckman Institute (https://speechaccessibilityproject.beckman.illinois.edu) is to collect, annotate, and curate a shared database of speech samples from…
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
- Trial name
- SAP (NCT05889260)
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- University of Illinois at Urbana-Champaign
Progressive Supranuclear Palsy, Spinal Cord Stimulation
The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy
The study is an open-label, prospective, single-arm, unicentral (Huashan Hospital Department of Neurology/ Neurosurgery) and exploratory clinical trial.
- Trial name
- NCT04367116
- Testing
- Spinal Cord Stimulation
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Huashan Hospital
Progressive Supranuclear Palsy
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists.
- Trial name
- NCT00382824
- Testing
- Coenzyme Q10
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Lahey Clinic
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENEREXT Study
This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202.
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Trial name
- NCT04604548
- Testing
- Oral administration of 100 mg KH176 twice daily
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Khondrion BV
Parkinson Disease, Multiple System Atrophy
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
- Trial name
- BUTTER2 (NCT07863180)
- Testing
- Tributyrin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Prabesh Kanel
Progressive Supranuclear Palsy, Parkinson Disease
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of…
- Conditions
- Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
- Trial name
- NCT04753320
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Massachusetts General Hospital
Essential Tremor, Multiple System Atrophy
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive
- Trial name
- PHENO (NCT02132052)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Colorado, Denver
Alzheimer Disease, Progressive Supranuclear Palsy
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD).
- Conditions
- Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia
- Trial name
- NCT05260151
- Where
- China
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Palsy Supranuclear, Supranuclear Palsy, Progressive
Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP).
- Trial name
- NCT04468932
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Corticobasal Syndrome, Progressive Supranuclear Palsy
Diagnosing Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
- Conditions
- Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia
- Trial name
- NCT02964637
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Mitochondrial Diseases, Kearns-Sayre Syndrome
Global Registry and Natural History Study for Mitochondrial Disorders
The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome…
- Conditions
- Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO
- Trial name
- GENOMIT (NCT05554835)
- Where
- 34 sites in Austria, Germany and 1 more
- Volunteers
- 6,000 people
- Sponsor
- LMU Klinikum
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS)
Safety Study of TPI-287 to Treat CBS and PSP
The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of…
- Conditions
- Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- TPI-287-4RT (NCT02133846)
- Testing
- TPI 287 2 mg/m2, TPI-287 20 mg/m2, TPI-287 6.3 mg/m2
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Progressive Supranuclear Palsy
Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)
The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).
- Trial name
- SCAN-PSP (NCT05579301)
- Where
- 2 sites in South Korea
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Mild Cognitive Impairment
Tau Imaging With JNJ067
This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, [18F] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
- Trial name
- NCT03926702
- Testing
- Radiopharmaceuticals
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease, Cortical Basal Syndrome
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
- Conditions
- Alzheimer's Disease, Cortical Basal Syndrome, Frontotemporal Dementia, Progressive Supranuclear Palsy
- Trial name
- NCT03625128
- Testing
- F-18
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Progressive Supranuclear Palsy (PSP)
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. It represents 5 to 10% of all parkinsonian syndromes and affects 3,000 to 10,000 persons in France.
- Trial name
- RIVA-PSP (NCT02839642)
- Testing
- Rivastigmine
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University